NO323951B1 - Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse - Google Patents

Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse Download PDF

Info

Publication number
NO323951B1
NO323951B1 NO20016034A NO20016034A NO323951B1 NO 323951 B1 NO323951 B1 NO 323951B1 NO 20016034 A NO20016034 A NO 20016034A NO 20016034 A NO20016034 A NO 20016034A NO 323951 B1 NO323951 B1 NO 323951B1
Authority
NO
Norway
Prior art keywords
amino
mmol
optionally substituted
isobutyl
benzyl
Prior art date
Application number
NO20016034A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016034L (no
NO20016034D0 (no
Inventor
Andrew Spaltenstein
Roger D Tung
Michael Robin Hale
Eric Steven Furfine
Istvan Kaldor
Stephen Price
Robin David Wilkes
Wayne Carl Schairer
Vicente Samano
John Franklin Miller
Michael Stephen Brieger
Ashley Nicholas Jarvis
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20016034D0 publication Critical patent/NO20016034D0/no
Publication of NO20016034L publication Critical patent/NO20016034L/no
Publication of NO323951B1 publication Critical patent/NO323951B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20016034A 1999-06-11 2001-12-10 Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse NO323951B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13907099P 1999-06-11 1999-06-11
US19021100P 2000-03-17 2000-03-17
PCT/US2000/015781 WO2000076961A1 (fr) 1999-06-11 2000-06-08 Inhibiteurs d'aspartyl protease

Publications (3)

Publication Number Publication Date
NO20016034D0 NO20016034D0 (no) 2001-12-10
NO20016034L NO20016034L (no) 2002-01-18
NO323951B1 true NO323951B1 (no) 2007-07-23

Family

ID=26836833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016034A NO323951B1 (no) 1999-06-11 2001-12-10 Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse

Country Status (31)

Country Link
EP (2) EP1194404B1 (fr)
JP (2) JP4503896B2 (fr)
KR (1) KR100762188B1 (fr)
CN (2) CN100516034C (fr)
AR (1) AR031520A1 (fr)
AT (2) ATE534622T1 (fr)
AU (1) AU779994B2 (fr)
BR (1) BR0011745A (fr)
CA (1) CA2380858C (fr)
CO (1) CO5160337A1 (fr)
CY (1) CY1112632T1 (fr)
CZ (1) CZ303052B6 (fr)
DE (1) DE60027722T2 (fr)
DK (2) DK1686113T3 (fr)
ES (2) ES2375823T3 (fr)
HK (1) HK1046899B (fr)
HU (1) HUP0300385A3 (fr)
IL (3) IL146918A0 (fr)
MX (1) MXPA01012808A (fr)
MY (1) MY137777A (fr)
NO (1) NO323951B1 (fr)
NZ (1) NZ516003A (fr)
PE (1) PE20010230A1 (fr)
PL (1) PL210227B1 (fr)
PT (2) PT1686113E (fr)
SI (1) SI1194404T1 (fr)
TN (1) TNSN00129A1 (fr)
TR (3) TR200603871T2 (fr)
TW (3) TWI318116B (fr)
WO (1) WO2000076961A1 (fr)
ZA (1) ZA200110177B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11573A (en) 1998-06-19 2004-07-01 Vertex Pharma Sulfonamide inhibitors of aspartyl protease.
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
CN100369904C (zh) * 2001-02-14 2008-02-20 泰博特克药品有限公司 2-(取代-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
MY142238A (en) * 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
CN1656109A (zh) * 2002-04-26 2005-08-17 吉里德科学公司 非核苷逆转录酶抑制剂
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
US20060148865A1 (en) * 2003-06-27 2006-07-06 Martin Michael T Preparation of chemical compounds
WO2005016900A1 (fr) 2003-08-18 2005-02-24 H. Lundbeck A/S Sel de succinate et de malonate de trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine et son utilisation en tant que medicament
PT1699455E (pt) * 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
WO2005087728A1 (fr) 2004-03-11 2005-09-22 Sequoia Pharmaceuticals, Inc. Inhibiteurs de la protease retrovirale inhibant la resistance
TWI383975B (zh) 2004-03-31 2013-02-01 Tibotec Pharm Ltd 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2006104646A1 (fr) * 2005-03-11 2006-10-05 Smithkline Beecham Corporation Inhibiteurs de proteases du vih
EP1971615B1 (fr) 2005-11-30 2014-01-01 TaiMed Biologics, Inc. Promedicaments d inhibiteurs d aspartyl protease a base de lysine et leurs procedes de fabrication
US20090312318A1 (en) * 2006-07-24 2009-12-17 Desai Manoj C Therapeutic compounds and methods
ES2359949T3 (es) 2006-11-09 2011-05-30 Tibotec Pharmaceuticals Métodos para preparar hexhidrofuro(2,3-b)furan-3-ol.
WO2008133734A2 (fr) * 2006-11-21 2008-11-06 Purdue Research Foundation Procédé et compositions utilisés pour traiter les infections à vih
SI2152667T1 (sl) 2007-04-27 2011-06-30 Tibotec Pharm Ltd Postopki za pripravo N-izobutil-N(2-hidroksi-3-amino-4-fenilbutil)-p- nitrobenzensulfonilamidnih derivatov
GB2452952A (en) * 2007-09-20 2009-03-25 Npil Pharmaceuticals N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
AU2010299959B2 (en) 2009-09-22 2016-07-21 Tibotec Pharmaceuticals Treatment and prevention of HIV infection
WO2011061590A1 (fr) 2009-11-17 2011-05-26 Hetero Research Foundation Nouveaux dérivés carboxamides comme inhibiteurs du vih
CN103193570B (zh) * 2013-04-09 2014-01-22 湖北来凤腾升香料化工有限公司 一种羟基高选择性保护方法
JPWO2016039403A1 (ja) * 2014-09-11 2017-06-29 塩野義製薬株式会社 持続性ｈｉｖプロテアーゼ阻害剤
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CA2032259A1 (fr) * 1989-12-18 1991-06-19 Wayne J. Thompson Inhibiteurs de la protease du vih utiles dans le traitement du sida
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
ES2059293T3 (es) * 1990-11-19 1998-12-16 Monsanto Co Inhibidores de proteasas retrovirales.
KR100336699B1 (ko) * 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
PT885881E (pt) * 1992-10-30 2003-07-31 Searle & Co Acidos sulfonilalcanoilamino hidroxietilamino sulfamicos uteis como inibidores de protease retroviral
EP0715618B1 (fr) * 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino-sulfonamides aptes a etre utilises comme inhibiteurs de protease retrovirale
CA2210889C (fr) * 1995-01-20 2007-08-28 G.D. Searle & Co. Inhibiteurs hydroxyethylamino contenant des bis-sulfinamides utilises pour inhiber des proteases retrovirales
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
DE69625183T2 (de) * 1995-03-10 2003-10-09 G.D. Searle & Co., Chicago Heterocyclocarbonyl-aminosäure-hydroxyethylamino-sulfonamid inhibitoren retroviraler proteasen
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
GB9712504D0 (en) * 1997-06-17 1997-08-20 Dundee Teaching Hospitals Nhs Thermal imaging method and apparatus
US6316405B1 (en) * 1997-08-26 2001-11-13 Wisconsin Alumni Research Foundation Cyclosporin a conjugates and uses therefor
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion

Also Published As

Publication number Publication date
IL202633A0 (en) 2010-06-30
NO20016034L (no) 2002-01-18
EP1686113B1 (fr) 2011-11-23
CY1112632T1 (el) 2016-02-10
CA2380858C (fr) 2011-12-06
IL202633A (en) 2013-02-28
KR20020033642A (ko) 2002-05-07
NZ516003A (en) 2004-02-27
MY137777A (en) 2009-03-31
ZA200110177B (en) 2003-01-13
JP4503896B2 (ja) 2010-07-14
ATE325091T1 (de) 2006-06-15
CZ303052B6 (cs) 2012-03-14
EP1686113A1 (fr) 2006-08-02
AR031520A1 (es) 2003-09-24
ES2263478T3 (es) 2006-12-16
PT1194404E (pt) 2006-08-31
TW593248B (en) 2004-06-21
BR0011745A (pt) 2002-03-19
WO2000076961A1 (fr) 2000-12-21
DE60027722T2 (de) 2007-04-26
JP2003502309A (ja) 2003-01-21
HK1046899B (zh) 2007-03-02
EP1194404A1 (fr) 2002-04-10
NO20016034D0 (no) 2001-12-10
TNSN00129A1 (fr) 2005-11-10
CZ20014431A3 (cs) 2002-06-12
DK1194404T3 (da) 2006-09-04
TR200603871T2 (tr) 2007-01-22
TWI299000B (en) 2008-07-21
HK1046899A1 (en) 2003-01-30
TW200425891A (en) 2004-12-01
CN1361765A (zh) 2002-07-31
DK1686113T3 (da) 2012-02-20
CN100516034C (zh) 2009-07-22
PL352830A1 (en) 2003-09-08
ATE534622T1 (de) 2011-12-15
CO5160337A1 (es) 2002-05-30
PE20010230A1 (es) 2001-03-15
AU779994B2 (en) 2005-02-24
IL146918A (en) 2010-06-16
TWI318116B (en) 2009-12-11
KR100762188B1 (ko) 2007-10-04
IL146918A0 (en) 2002-08-14
CA2380858A1 (fr) 2000-12-21
HUP0300385A3 (en) 2007-05-29
AU5600600A (en) 2001-01-02
PT1686113E (pt) 2012-02-20
SI1194404T1 (sl) 2006-10-31
ES2375823T3 (es) 2012-03-06
MXPA01012808A (es) 2002-07-22
TW200804252A (en) 2008-01-16
CN101245058A (zh) 2008-08-20
DE60027722D1 (en) 2006-06-08
EP1194404B1 (fr) 2006-05-03
PL210227B1 (pl) 2011-12-30
JP2009046493A (ja) 2009-03-05
TR200202528T2 (tr) 2003-02-21
HUP0300385A2 (hu) 2003-07-28
TR200200407T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
NO323951B1 (no) Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse
US6617350B2 (en) Inhibitors of aspartyl protease
US8455497B2 (en) Inhibitors of aspartyl protease
ES2235492T3 (es) Inhibidores de aspartil proteasa de tipo sulfonamida.
JP2010184932A (ja) アスパルチルプロテアーゼのインヒビター
US6878728B1 (en) Inhibitors of aspartyl protease
MXPA00012637A (en) Sulfonamide inhibitors of aspartyl protease

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees